Tonix Pharmaceuticals to Present at Guggenheim Healthcare Innovation Conference, Highlighting Pipeline and Commercial Growth

Tonix Pharmaceuticals' upcoming presentation at the Guggenheim conference underscores its progress in CNS and immunology, including its newly approved fibromyalgia treatment and pipeline candidates.

Houston Metrowire Staff
••Healthcare
Tonix Pharmaceuticals to Present at Guggenheim Healthcare Innovation Conference, Highlighting Pipeline and Commercial Growth

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated, commercial-stage biopharmaceutical company, will present at Guggenheim's 3rd Annual Healthcare Innovation Conference in Boston on Nov. 10, 2026. President and CEO Seth Lederman, M.D., will deliver the company presentation from 4 to 4:25 p.m. ET, with one-on-one meetings also scheduled. A live webcast and replay will be available under the News & Events tab in the Investors section of the company's website.

The presentation comes at a pivotal time for Tonix, which recently received approval for TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in more than 15 years. This approval marks a significant milestone, providing a novel option for patients with this chronic pain condition. Tonix's CNS commercial infrastructure supports its marketed products, including acute migraine treatments Zembrace(R) SymTouch(R) and Tosymra(R), and the company is maximizing the science behind TONMYA in Phase 2 trials for major depressive disorder and acute stress disorder, potentially expanding its use to larger patient populations.

Beyond its commercial products, Tonix is advancing a diverse pipeline. TNX-2900 is Phase 2 ready for Prader-Willi syndrome, a rare disease with high unmet need. The immunology programs include TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. These programs target areas where current therapies are limited, and successful development could drive long-term growth.

Investors can access the full press release at https://ibn.fm/f7udM, and the latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. The conference presentation offers an opportunity for Tonix to engage with the investment community and highlight its strategic vision.

The announcement was distributed through InvestorWire, a specialized communications platform that is part of the Dynamic Brand Portfolio at IBN. InvestorWire provides wire-grade press release syndication and editorial syndication to 5,000+ outlets, along with social media distribution and other corporate communications solutions. This broad reach ensures that Tonix's news is widely disseminated to investors and other stakeholders.

The presentation at the Guggenheim conference is important because it allows Tonix to showcase its recent approval and pipeline progress to a targeted audience of healthcare investors. With TONMYA's launch and the advancement of its CNS and immunology programs, Tonix is positioning itself for potential growth. The conference appearance could enhance visibility and attract investment as the company continues to develop treatments for unmet medical needs. For full terms of use and disclaimers, visit https://www.InvestorWire.com/Disclaimer.

Blockchain Registration

QR Code for Blockchain Registration